Novartis Kisqali significantly prolongs life in women with HR+/HER2- advanced breast cancer now in two distinct Phase III trials

    NEXT STORY
    Teladoc Health Reports Second Quarter 2019 Results
    PREV STORY
    BioRestorative Therapies Signs $5.4 Million Financing with Institutional Investor
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Hemispherx Biopharma Inc. Announces Advancement in Expanded Access Program for Ampligen in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

    Second Large Shipment Dispatched to Second Major ClinicOCALA, Fla., Jan. 02, 2019 (GLOBE NEWSWIRE) ...

    author_avatar
    NASDAQ Market News

    Onconova Presents Promising Data from Phase 2 Expansion Study of Oral Rigosertib and Azacitidine Combination in Patients with Myelodysplastic Syndromes at 6th International Bone Marrow Failure Disease Symposium

    First presentation from dose exploration cohorts in an expanded trial addressing urinary safety of ...

    author_avatar
    NASDAQ Market News

    Rejuvenate Reverses Muscle Loss From Aging Without Exercise

    author_avatar
    NASDAQ Market News